Kenya is among nine countries selected to introduce Lenacapavir antiretroviral medication, a groundbreaking long-acting injectable pre-exposure prophylaxis (PrEP), by January 2026.
The other eight countries are Eswatini, Lesotho, Mozambique, Nigeria, South Africa, Uganda, Zambia, and Zimbabwe.
Health Cabinet Secretary Adan Duale, in a statement Tuesday, said this milestone underscores the government's collective determination to expand access to effective, discreet, and sustainable prevention options across the region.
He added that with the current national HIV prevalence standing at 3.7 percent, 1.4 million people living with HIV, and a concerning 41 per cent of new infections among youth under 24 years, the urgency for impactful and tailored solutions has never been greater.
